Holen Sie sich die Stockscreener-App
20.35
3.19%
0.63
Vorhandelsmarkt:
20.03
-0.32
-1.57%
Schlusskurs vom Vortag:
$19.72
Offen:
$19.96
24-Stunden-Volumen:
6.10M
Relative Volume:
5.31
Marktkapitalisierung:
$2.17B
Einnahmen:
$247.00M
Nettoeinkommen (Verlust:
$-249.00M
KGV:
-6.5858
EPS:
-3.09
Netto-Cashflow:
$-267.00M
1W Leistung:
+9.41%
1M Leistung:
+52.43%
6M Leistung:
+123.14%
1J Leistung:
+31.29%
1-Tages-Spanne:
$19.65
$20.68
1-Wochen-Bereich:
$18.32
$22.11
52-Wochen-Spanne:
$6.50
$22.11
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Vergleichen Sie RCUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
20.35 | 2.13B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Does Arcus Biosciences Inc. show high probability of rebound2025 Market Sentiment & Free Reliable Trade Execution Plans - newser.com
Latham & Watkins Advises Arcus Biosciences in US$250 Million Public Offering of Common Stock - Legal Desire Media and Insights
Arcus Biosciences Completes Successful Stock Offering - TipRanks
Arcus Biosciences Completes Public Offering of Common Stock - TradingView
Is Arcus Biosciences Inc. stock a buy on dipsJuly 2025 Decliners & Daily Stock Trend Reports - newser.com
Automated trading signals detected on Arcus Biosciences Inc.Trade Volume Report & Consistent Profit Focused Trading Strategies - newser.com
Mizuho Raises Price Target on Arcus Biosciences to $47 From $45, Keeps Outperform Rating - MarketScreener
Why Arcus Biosciences Inc. stock is rated strong buyTrade Exit Summary & Verified Stock Trade Ideas - newser.com
What is the fair value estimate for Arcus Biosciences Inc. stock in 2025Trade Analysis Report & Expert-Curated Trade Recommendations - newser.com
Visual analytics tools that track Arcus Biosciences Inc. performanceBuy Signal & Weekly Breakout Watchlists - newser.com
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo! Finance Canada
Price action breakdown for Arcus Biosciences Inc.2025 Top Decliners & AI Driven Price Predictions - newser.com
What dividend safety score for Arcus Biosciences Inc. stockJuly 2025 Market Mood & Weekly High Potential Stock Alerts - newser.com
Risk adjusted return profile for Arcus Biosciences Inc. analyzedWeekly Investment Summary & AI Forecasted Entry and Exit Points - newser.com
Should you hold or exit Arcus Biosciences Inc. nowJuly 2025 Market Mood & Low Risk Investment Opportunities - newser.com
Why Arcus Biosciences Inc. stock appears on watchlistsQuarterly Trade Summary & Verified Entry Point Signals - newser.com
How moving averages guide Arcus Biosciences Inc. trading2025 Big Picture & Breakout Confirmation Trade Signals - newser.com
Using AI based signals to follow Arcus Biosciences Inc.2025 EndofYear Setup & Risk Managed Investment Signals - newser.com
Reversal indicators forming on Arcus Biosciences Inc. stockJuly 2025 Snapshot & Weekly Watchlist for Hot Stocks - newser.com
Arcus Biosciences announces launch of public offering - MSN
Arcus Biosciences prices $250M offering - MSN
Arcus Biosciences (NYSE:RCUS) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Analyzing recovery setups for Arcus Biosciences Inc. investorsWeekly Investment Recap & High Accuracy Trade Signal Alerts - newser.com
Arcus Biosciences (NYSE:RCUS) Shares Gap Down on Insider Selling - MarketBeat
Arcus Biosciences, Inc. (NYSE:RCUS) Just Reported, And Analysts Assigned A US$29.60 Price Target - simplywall.st
Arcus Biosciences, Inc. (NYSE:RCUS) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
FY2025 EPS Estimates for RCUS Increased by Analyst - MarketBeat
Wedbush Increases Earnings Estimates for Arcus Biosciences - MarketBeat
HC Wainwright Has Positive Forecast for RCUS FY2025 Earnings - MarketBeat
Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 19,019 Shares - MarketBeat
Insider Selling: Arcus Biosciences (NYSE:RCUS) President Sells 77,840 Shares of Stock - MarketBeat
Arcus Biosciences stock falls after pricing $250 million public offering By Investing.com - Investing.com Nigeria
Arcus Biosciences launches public offering of common stock By Investing.com - Investing.com Australia
Arcus Biosciences stock falls after pricing $250 million public offering - Investing.com
Analysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG), TransMedics Group (TMDX) and Arcus Biosciences (RCUS) - The Globe and Mail
Arcus Biosciences (RCUS) Announces Pricing Details for Recent Of - GuruFocus
Arcus Biosciences falls after $250 mln stock sale - TradingView
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Beats Revenue Estimates - MSN
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):